A rare pitfall in the molecular interpretation of BRAF V600E status in melanoma in the setting of BRAF V600E-mutated chronic lymphocytic leukemia/small lymphocytic lymphoma.

BRAF mutation status is a critical predictive and prognostic biomarker in guiding management of unresectable and metastatic melanoma. We recently observed a case of BRAF V600E-mutated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) intermixed with BRAF V600E wild-type melanoma reported to harbor BRAF V600E mutation on molecular testing. Our observation underscores the importance of appropriate tumor selection for molecular studies and knowledge of mutational status of co-existing tumors. This article is protected by copyright. All rights reserved.